ClinicalTrials.gg
CompletedNCT03417596Updated Jan 31, 2018

Vestibular Rehabilitation in Patients With Vestibular Migraine

An interventional study of Control and Vestibular Rehabilitation in Vestibular Migraine, Vestibular Disorder and Migraine Variant, sponsored by Ege University. Completed. Per ClinicalTrials.gov, last updated 2018-01-31.

Sponsored by Ege University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2015, registered Jan 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Randomized
Sex
All
01

Study summary

Abstract: Introduction:

Vestibular migraine(VM) is a disease that manifests with episodic vertigo attacks in patients with or without migraine type headaches, when present accompanying the headaches. Its prevalence was found out as %1 in a study in Germany. It usually involves middle aged women. VM can make a huge impact on quality of life, therefore advances in its diagnosis and management are valuable. While pharmacotherapy that is being used in migraine can be beneficial, vestibular rehabilitation(VR) programmes are predicted to be one of the most important types of treatment in management of VM. This study compares the results of pharmacological management options and vestibular rehabilitation programmes in the context of dizziness, balance problems and headache.

Material and methods:

77 patients with VM were included in study, and 60 of them completed it. While one group took only VR programme, and another took only pharmacological prophylaxis. The third group took a combined therapy, and the groups were consisted of 20 patients. Patients were assessed with caloric tests, audiometric studies, static posturography, Dizziness Handicap Inventory(DHI), and Activities Specific Balance Confidence(ABC) scales. All of the assessments were applied 3 times throughout the study, and the results were compared with relevant statistical tests.

02

Conditions studied

  • Vestibular Migraine
  • Vestibular Disorder
  • Migraine Variant
03

In context

Vestibular Diseases

170 studies on the registry are indexed under Vestibular Diseases; 41 are open to participants now.

This study's enrollment of 77 is above the median of 46 across 127 interventional studies indexed under Vestibular Diseases.

Browse Vestibular Diseases studies →

Lead sponsor

Ege University is the lead sponsor of 376 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1-Vestibular Migraine diagnosis according to International Classification of Headache Disorders (3 rd edition-Beta version) 2- No history of vestibular rehabilitation or exercises

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric disorder which might interfere with compliance to study
  • Other diagnosis that might possibly cause vestibular disorder(cerebellar disorders, Meniere disease etc)
  • Anatomical defects of the inner ear or vestibular system
  • Patients who are unable to stand up straight or walk
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Vestibular Rehabilitation

    Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day. Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around. Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides. The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit.

    Behavioral: Vestibular Rehabilitation

  • Experimental
    Vestibular Rehabilitation+Pharmacological Therapy

    Same exercises that were applied in first group were also applied to this group. For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.

    Other: Control · Behavioral: Vestibular Rehabilitation

  • Other
    Pharmacological Therapy only

    Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.

    Other: Control

Interventions

  • OtherControl

    Routine treatment

  • BehavioralVestibular Rehabilitation

    Exercise and rehabilitation programme was individualized

06

What researchers measure

Primary outcomes

  1. Dizziness Handicap Inventory

    A standardized inventory to assess the impact of dizziness in patients' life.

    Time frame: 6 months

  2. Activities-specific balance confidence scale

    A scale which is used to evaluate balance confidence of patients in some specific activities. Confidence in daily activities requiring balance is rated by subject as percentage(from %0 to %100). Higher percentage relates to better confidence in balance.

    Time frame: 6 months

  3. Static Posturography

    Static posturography was performed using the NeuroCom System Version 8.0.3 (NeuroCom International Inc., Clackamas, OR, USA). Mean center of gravity (COG) sway velocity (°/s) was recorded on a static platform with eyes open (ST-EO) and closed (ST-EC) and on foam with eyes open (FO-EO) and closed (FO-EC)

    Time frame: 6 months

Secondary outcomes

  1. Vertigo attack severity

    Self reported outcome in which patients give insight about their vertigo attack severity

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Apr 2016, 15 months.

Of 79 non-industry interventional studies with no phase under Vestibular Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's 15 months is close to that.

Counting every sponsor, half of 84 studies reached it within 15 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2018
First posted
Jan 31, 2018
StartActual
Jan 10, 2015
Primary completionActual
Apr 10, 2016
CompletionActual
Apr 15, 2016
Last update
Jan 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03417596
Lead sponsor
Ege University
Responsible party
Figen Gökçay (Professor in Ege University School of Medicine, Neurology Department, MD, Ege University) — Principal investigator
First posted
Jan 31, 2018
Start date
Jan 10, 2015
Primary completion
Apr 10, 2016
Completion
Apr 15, 2016
Last update
Jan 31, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion